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PURPOSE. Antitumor T cells need expression of HLA class I molecules but can be inhibited by
ligands such as programmed death ligand 1 (PD-L1). We determined expression and
regulation of these molecules in human conjunctival melanoma (CM) samples, cell lines, and
murine xenografts.
METHODS. Immunofluorescence staining was performed to examine the expression of HLA-A,
HLA-B/C, and b-2-microglobulin (B2M) in 23 primary CM samples. HLA class I expression was
compared with clinicopathologic characteristics, the presence of tumor-infiltrating leuko-
cytes, and PD-L1/PD-1 status. The effect of interferon c (IFN-c) on HLA class I expression was
tested on three CM cell lines using quantitative PCR and flow cytometry. Furthermore, HLA
class I expression was determined in CM cell line–derived murine xenografts.
RESULTS. One third of tumors had positive HLA-A, HLA-B/C, and B2M expression. A positive
expression was especially seen in thin and epibulbar tumors but was not associated with
recurrences. HLA class I expression was correlated with M2 macrophage density and tended
to associate with CD8þ T-cell density but was independent of PD-L1 or PD-1 expression. IFN-c
upregulated HLA class I expression and genes involved in HLA transcription and
transportation on CM cell lines. Murine xenografts showed a comparable HLA class I
expression as their respective cell lines.
CONCLUSIONS. Our data indicate that subsets of CM have positive HLA class I expression, and
HLA class I and PD-L1/PD-1 are expressed independently. When one considers immunother-
apy, one should also analyze HLA class I expression, whose downregulation can limit the
efficacy of T cell–mediated therapies.
Keywords: conjunctival melanoma, HLA class I, immune escape, animal model, tumor
infiltrating lymphocytes
Currently, a lot of attention is given to the role of theimmune system in tumor growth, control, and treatment.
The theory of immune surveillance, which states that the
immune system can recognize and destroy tumor cells, has
been widely accepted and provides targets for therapy.1 The
discovery of immune checkpoint regulators has transformed
the treatment of many malignancies: cancer often protects itself
from T-cell attack by blocking T-cell signals. Binding of
programmed death ligand 1 (PD-L1) on the cancer cell to PD-
1 on the T cell will suppress the T cell’s function, impair
cytokine production, and induce T-cell apoptosis. To reverse
this immunologically tolerant state, antibodies against these
immune checkpoints have been developed (e.g., targeting PD-1
or cytotoxic T-lymphocyte-associated protein 4 [CTL-A4]). The
results in cutaneous melanoma, bladder cancer, non–small cell
lung cancer, and mucosal melanoma are promising but
restricted to subsets of patients.2–5
Expression of the HLA class I molecules is needed to
recognize and lyse tumor cells by cytotoxic T cells (CTLs): CTLs
can destroy cells that express the appropriate peptide/MHC
class I complex.6 HLA class I molecules consist of a
glycoprotein heavy chain (coded in the HLA region on
chromosome 6p21) and a b-2-microglobulin (B2M) light chain
(gene located on chromosome 15).7 Defects in HLA class I
antigen-processing machinery (APM) components impair effec-
tive immune responses to cancer, although tumor-infiltrating
lymphocytes may still present. A lack of HLA class I expression
that may be associated with a worse survival8 has been
described in many malignancies and can either be ‘‘soft’’
(reversible) or ‘‘hard’’ (irreversible), due to various mecha-
nisms.9 A low HLA expression can often be corrected by
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interferon-c (IFN-c), thereby restoring a tumor cell’s suscepti-
bility to be lysed by T cells.
Although a lot of immunologic research in melanoma has
focused on cutaneous lesions, little is known about melanoma
of the conjunctiva. Conjunctival melanoma (CM) is a rare type
of mucosal melanoma that originates in the melanocytes of the
basal layer of the conjunctiva and accounts for 5% of all ocular
melanoma.10 The incidence in Caucasians is 0.8/million11 and
in recent years has been increasing in Western countries.12,13
The appearance of CM ranges from amelanotic to heavily
pigmented and CM can occur in any part of the epibulbar or
nonepibulbar conjunctiva. Wide local excision with adjuvant
treatment (cryotherapy, chemotherapy, brachytherapy) is the
most common therapy, whereas more extensive surgical
procedures are reserved as a last resort therapy.14 Despite
treatment, recurrence rates of 26% to 61% at 5 years after
treatment have been reported,15–18 with metastases occurring
in 11% to 16% of patients.15,19 Because limited chemothera-
peutic options are available for extended or metastasized CM,
these patients may benefit from the new T cell–mediated
treatments. We recently described that PD-1– and PD-L1–
positive cells are present in CM,20 making treatment with PD-
L1/PD-1 inhibitors potentially interesting. Very recently,
Nivolumab (PD-1 inhibitor, Opdivo, Bristol-Myers Squibb, NY,
USA) led to a successful clinical response in a CM patient with
breast metastases.21
However, effective T-cell immune responses also need a
proper expression of the HLA class I antigens. Currently, very
little is known regarding the expression of the HLA class I
antigens in CM. We studied the degree of HLA class I
expression in human CM samples, CM cell lines, and animal
xenografts. We found out that HLA class I expression was not
associated with PD-L1/PD-1 status and detected positive HLA
class I expression in only one third of primary CM.
METHODS
Patient Data and Selection
Patients were treated at the Leiden University Medical Center
(LUMC), Leiden, The Netherlands, between 1996 and 2014.
The tumor cohort included 23 primary CM for which sufficient
material was available (Table 1). Tumors were examined by an
experienced ophthalmic pathologist (SD). Tumor stage was
assessed according to the 7th edition of the American Joint
Committee on Cancer (AJCC) classification of malignant
tumors (TNM) cancer staging manual.22 Local recurrence was
defined as a histologically proven recurrence. Metastasis was
verified by histologic examination or imaging analysis. Total
follow-up time was from the time of diagnosis to the last
known status. The study adhered to the tenets of the
Declaration of Helsinki, and the Medical Ethical Committee
of LUMC agreed with this retrospective study.
Immunohistologic Staining and Scoring
Immunofluorescence (IF) staining of HLA-A, HLA-B/C, and
B2M on human paraffin-embedded CM sections was per-
formed as previously described.19,23 For immunohistochem-
istry (IHC) on mouse xenografts, the procedures were
performed as described.24 In short, primary antibodies
HCA2 (mouse, anti-HLA-A, IgG1, MUB2036P, 1:50; Nordic
Mubio, Uden, The Netherlands), HC10 (mouse, anti-HLA-B/C,
IgG2a, MUB2037P, 1:100; Nordic Mubio), and B2M (rabbit,
Z0311, 1:2000 [IHC], 1:1000 [IF]; DAKO, Glostrup, Den-
mark) were used for both IF and IHC staining. Isotype control
staining was obtained by replacing primary antibodies with
control antibodies with respective isotypes antibodies. The
detailed information of secondary antibodies is in Supple-
mentary Table S1. IF images were taken using a Zeiss LSM 700
confocal scanning microscope (Zeiss, Breda, The Nether-
lands). Based on the tumor size, one to five representative
images at high power (2503) were randomly selected from
different areas for scoring. Tumor areas were distinguishable
from normal tissue by DAPI (4 0,6-diamidino-2-phenylindole;
H-1200; Vector Laboratories, Burlingame, CA, USA) staining.
Two experienced independent observers (JC and NB or EJ),
blinded to the clinicopathologic data, evaluated the intensity
and percentage of HC10, HCA2, and B2M expression
separately. In case of discrepancies, a consensus was reached
by simultaneous analysis. The semiquantitative scoring
system was obtained from prior studies23,25–27: intensity
was scored as 0 (absent), 1 (weak), 2 (moderate), and 3
(strong), and the percentage of positive cells as 0 (0%), 1 (1%
to 5%), 2 (6% to 25%), 3 (26% to 50%), 4 (51% to 75%), and 5
(76% to 100%). A single value was reached by adding
intensity and percentage and was used to create three
categories: negative (0 to 2), weak (3 to 6), and positive
expression (7 to 8). Stromal cells served as an internal
positive control. The B2M staining of one tumor was not
scorable and was therefore excluded. The images of
hematoxylin and eosin (HE) staining were captured using
the Philips Image Management System 2.2 (Philips, Eind-
hoven, The Netherlands). The staining and scoring method of
tumor-infiltrating lymphocytes (CD3, CD3þCD8þ, CD3þCD8,
CD3þCD8Foxp3þ, and CD3þCD8Foxp3 T cells, and CD68
and CD68þCD163þ macrophages) was performed as previ-
ously described.20 Expression of PD-L1 on tumor or stromal
cells and of PD-1 was determined as described.20
HLA Typing
HLA typing was performed at the Laboratory of the Depart-
ment of Immunohematology and Blood Transfusion (IHB,
LUMC) using the Gen-Probe LIFECODES HLA-SSO HLA typing
assay for HLA class I typing.
Cell Lines and Treatment
Three CM cell lines (CRMM1, CRMM2, and CM2005.1) derived
from primary tumors, kindly provided by Michele Madigan
(Sydney, Australia) and Sander Keijser (Leiden University
Medical Center, Leiden, The Netherlands), were used.28,29 To
examine the influence of IFN-c on HLA class I expression, CM
cells were cultured with or without 100 IU/mL of IFN-c
(ImmunoTools, Friesoythe, Germany) for 48 hours.30
RNA Isolation and Quantitative Real-Time PCR
The isolation of total cellular RNA, complementary DNA
conversion, and quantitative PCR (qPCR) was performed based
on a standard protocol of our laboratory, as described
previously.31 Primer sequences are in Supplementary Table
S2. CFX Manager 3.1 (Bio-Rad, Hercules, CA, USA) software
was used to analyze the data: the Ct values of each sample were
normalized against the geometric mean Ct values of house-
keeping genes (RPS11 and RPL13).
Flow Cytometry
Cells were incubated with anti-HLA class I antibody (W6/32,
311414, Alexa Fluor 647; BioLegend, San Diego, CA, USA) to
detect total HLA class I expression. HLA allele–specific
monoclonal antibodies were obtained from the IHB Depart-
ment, LUMC (Supplementary Table S3)32,33 and were applied
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for detecting HLA allele–specific expression. Appropriate FITC
(F0315; DAKO) or RPE (R5111; DAKO) secondary antibodies
were selected. Cells were collected (10,000 to 50,000 cells per
live gate) using Accuri C6 or FACSCalibur cytometer (Beckton
Dickinson, Vianen, The Netherlands). Results were analyzed
with FlowJo software (V10.0.7; Flowjo LLC, Ashland, OR,
USA).
In Vivo Xenografts
The murine paraffin-embedded tumor sections were obtained
from the stored blocks from our previous study.24 The
establishment of the murine model was stated as below.
Briefly, nonobese diabetic (NOD)/severe combined immuno-
deficiency (SCID) IL-2 receptor c chain null mice were
subconjunctivally injected with one of three CM cell lines.
Subsequently, cells (CRMM1 and CM2005.1) obtained from
established CM tumor xenografts were reinjected into the
subconjunctival space of the second set of NOD/SCID mice.
This in vivo passaging technique led to lung metastases (9
weeks after subconjunctival injection). The animal experiment
was maintained under the guidelines of the Schepens Eye
Research Institute, Boston, MA, USA, and experiments were
carried out based on the guidelines for the use of animals in
research of the Association for Research in Vision and
Ophthalmology.
Statistical Analysis
Data were analyzed with SPSS software version 22.0 (SPSS, Inc.,
Chicago, IL, USA). Statistical significance was defined as P 
0.05. The Fisher-Freeman-Halton test and Kruskal-Wallis test
were used. Paired t-test (2-tailed) was used to analyze the
upregulation of HLA-related genes on IFN-c treatment.
RESULTS
Frequent Downregulation of HLA Class I
Expression in Primary CM
HCA2 and HC10 recognize HLA-A and HLA-B/C, respectively.34
B2M is a component of the HLA class I complex.35 We used
triple IF staining to determine the percentage of positively-
stained tumor cells and the intensity of staining on formalin-
fixed, paraffin-embedded sections of 23 human primary CM
(Fig. 1). Expression of HLA-A, HLA-B/C, and B2M correlated
strongly (Table 2). Four (17%) cases showed no staining of
HLA-A, three (13%) cases showed no expression of HLA-B/C,
and three cases (14%) showed no staining of B2M (Table 1).
Twelve (52%), 13 (57%), and 11 (50%) cases exhibited weak
expression (scores 3 to 6) of HLA-A, HLA-B/C, and B2M,
respectively, with the remaining tumors showing a positive
expression of B2M, HLA-A, and HLA-B/C. Heterogenous HLA
class I expression was seen in three cases, as presented in
Figure 2.
Patient Characteristics
We correlated expression levels of HLA-A, HLA-B/C, and B2M
with clinical and histopathologic data (Table 1; Supplemen-
tary Table S4). The mean age of the patients at diagnosis was
62.6 (SD 14.3) years, and 13 of the 23 patients (57%) were
women. The median follow-up time was 42 months (range, 3
to 249 months). At the end of the follow-up, 10 (43%) patients
had developed local recurrences, 3 (13%) had died from CM
metastases, 2 (9%) had died from unknown causes, and 18
(78%) patients were alive. Local recurrence was only related
to tumor largest basal diameter (P¼ 0.046) and not to tumor
thickness (P¼ 0.24) or TNM stage (P¼ 0.089). HLA-A, HLA-B/
C, or B2M expression was not correlated with largest basal
diameter, local recurrence, metastasis formation, or melano-
ma-related survival. Epibulbar/T1 tumors had a higher HLA
class I expression than nonepibulbar/T2 tumors (P ¼ 0.03,
HCA2; P ¼ 0.046, B2M; Table 1). Thicker tumors showed a
lower HLA-A and B2M expression than the thinner tumors (P
¼ 0.03 and 0.046, respectively), with a trend for downregu-
lation of HLA-B/C (P ¼ 0.08). Additionally, thick tumors had
fewer CD68þCD163þ macrophages (r ¼ 0.56, P ¼ 0.01).
Expression of HLA class I was associated with the number of
CD68þCD163þ macrophages in the tumor area (P ¼ 0.03,
HCA2; P¼ 0.07, HC10; P¼ 0.02, B2M; Table 2) and tended to
correlate with CD8þ T-cell density (P¼ 0.09, HCA2; P¼ 0.10,
HC10; P ¼ 0.14, B2M; Table 2). These data suggest that
macrophages and T cells play a role in stimulating HLA class I
expression in CM (Table 2). Expression of PD-L1 on tumor or
stromal cells and of PD-1 occurred independently of HLA class
I expression (Table 1 and Cao et al.20).
mRNA and Membrane Expression of HLA Class I in
CM Cell Lines
To better understand the regulation of HLA class I expression
in CM, we studied three CM cell lines. For this, we first
performed HLA-DNA typing (Table 3). CRMM1 genetically
carries the HLA-A*02:01 allele, which is a very attractive
genotype, because thus far, most of the clinical T-cell receptor
(TCR) cancer therapies are HLA-A*02:01 restricted.
Next, we determined expression of HLA-A, HLA-B, and B2M
on the three cell lines and analyzed the effect of IFN-c, which is
a known HLA stimulator. HLA allele–specific antibodies were
selected according to the results of the HLA DNA typing. Flow
cytometry analysis showed that most genetically determined
HLA class I antigens were expressed, except for HLA-A2 and
HLA-B44 on CRMM1 and HLA-B44 on CRMM2 (Fig. 3A). IFN-c
treatment increased the expression of most alleles, except for
HLA-A2 on CRMM1 and HLA-B44 on CRMM2, indicating a hard
loss of HLA antigens.
When loss of expression was observed, we set out to
determine whether there was a normal activity of the
transcriptional regulators (CIITA, IRF1, and NLRC5) and genes
encoding the peptide-loading machinery (TAP1 and TAP2),
using specific primers and qPCR. NLRC5 is essential for HLA
class I transcription, whereas CIITA and IRF1 are involved in
HLA class I, as well as class II transcriptional regulation. TAP1
and TAP2 transport peptides from the cytoplasm to the
endoplasmic reticulum and present these peptides to MHC
class I molecules.35 Figure 3B shows that the three CM cell
lines presented various baseline mRNA levels of the regulator
genes. mRNA expression of not only HLA-A, HLA-B, and B2M,
but also of CIITA, IRF1, NLRC5, TAP1, and TAP2 was increased
after IFN-c stimulation, indicating that these molecules were
normally responsive.36
HLA Class I Expression Was Maintained in Animal
Xenografts
We previously established a CM metastasis model using in
vivo passaging24 and wondered whether in vivo placement of
the tumor cell lines affected HLA expression. Because
immunodeficient mice were used, the HLA class I expression
on xenografts would not be influenced by local infiltration
with T lymphocytes and environmental cytokines, thus
showing the tumor’s ‘‘natural’’ expression. IHC staining
using HCA2, HC10, and B2M antibodies showed that HLA
class I expression of CM cells was maintained in the murine
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FIGURE 1. Immunofluorescence analysis of HLA class I expression. Representative pictures of triple staining show expression on CM cells in one
tumor (A) and on T cells in another (B): similar membrane expression patterns are seen for the antibodies HCA2 (HLA-A, green), HC10 (HLA-B/C,
red), and B2M (HLA class I, blue), respectively. White arrows indicate T cells surrounding the tumor area. Scale bar denotes 50 lm.
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(HC10) B2M CD3 CD3þCD8þ CD3þCD8 CD3þCD8Foxp3- CD3þCD8Foxp3þ CD68 CD68þCD163þ
Thickness
r 0.49 0.50 0.53 0.35 0.39 0.32 0.33 0.27 0.35 0.50
P 0.02 0.02 0.01 0.12 0.08 0.16 0.15 0.23 0.12 0.02
HLA-A (HCA2)
r – 0.94 0.97 0.25 0.36 0.17 0.18 0.22 0.40 0.45
P – <0.01 <0.01 0.25 0.09 0.45 0.41 0.31 0.06 0.03
HLA-B/C (HC10)
r – – 0.97 0.29 0.36 0.18 0.15 0.33 0.30 0.38
P – – <0.01 0.18 0.10 0.40 0.51 0.13 0.16 0.07
B2M
r – – – 0.31 0.33 0.24 0.25 0.28 0.43 0.49
P – – – 0.17 0.14 0.27 0.25 0.21 0.04 0.02
P  0.05 are in italics. The staining and scoring method is previously described.16 r, 2-tailed Spearman correlation coefficient, with 23
observations.
FIGURE 2. Heterogeneous expression of HLA class I antigens in a CM. Representative IF staining shows membranous HCA2 (HLA-A, green), HC10
(HLA-B/C, red), and B2M (HLA class I, blue) expression only in the lower part of the tumor area. White arrows indicate areas of positive expression.
Scale bar denotes 50 lm.
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models in the same manner as on the cell lines in vitro (Fig. 4;
Table 4). There seemed a trend toward a decrease of HLA
class I expression during tumor progression (primary in vivo
passaged metastasis; Fig. 4); however, HLA class I was
expressed at all stages.
DISCUSSION
We investigated expression of HLA class I molecules in
primary CM and compared HLA class I expression with
clinical parameters. In only a third of CM did we observe a
positive expression of HLA-A (~30%), HLA-B/C (~30%), and
B2M (~36%). The presence of a negative or weak HLA class I
antigen expression in approximately 70% of CM is similar to
that of bladder cancer, but higher than of cutaneous
melanoma and intrahepatic cholangiocarcinoma.37,38 Several
factors may contribute to this observed lack of HLA class I
antigen expression: mutations or loss of heterozygosity (LOH)
in chromosomes 6 or 15 (where B2M is located), or prior
immune selection, leaving only HLA class I negative tumor
cells.39 We did indeed find some tumors that lacked B2M, but
do not have information on mutations in this gene. An absent
or low expression of HLA class I has been associated with a
worse survival in patients with advanced cutaneous melano-
ma, cervical cancer, and rectal cancer.26,40,41 We did not find a
correlation between HLA class I expression and melanoma-
related survival in primary CM. However, we did notice that
an aberrant HLA class I expression was significantly correlat-
ed with one of the known prognostic factors known
prognostic factors (i.e. tumor thickness), which is concordant
with previous investigations in cervical cancer and cutaneous
melanoma.42,43 The association of HLA class I expression with
M2 macrophages and CD8þ T cells suggests a connection of
IFN-c with HLA class I expression in the tumor. The cytokine
IFN-c, mainly secreted by CD4 Th1, CD8 T lymphocytes,
macrophages, and natural killer (NK) cells,44 is known to be a
key modulator of HLA expression. The data on expression and
regulation of most of the HLA antigens on three unique CM
cell lines, using HLA DNA typing, qPCR, and flow cytometry,
indeed confirmed this theory: after IFN-c treatment, mRNA
expression levels of CIITA, IRF1, NLRC5, TAP1, and TAP2
were increased, together with HLA class I molecules. Our
finding is similar to previous investigations using uveal
melanoma cell lines.36 Interestingly, the flow cytometry data
showed that not all alleles were expressed on the cell surface:
although the HLA-A*02:01 and HLA-B*44:02 alleles were
detected by HLA DNA typing, they were not expressed on
the cell surface of CRMM1 and CRMM2, respectively. This
result may be explained by allele-specific mutations or by post
translational instability due to a missing disulfide bridge.45
This remains to be investigated.
To further test our theory that the presence of infiltrating
immune cells plays a role in HLA expression, we looked at
murine xenografts that were obtained by injection of three
CM cell lines into the subconjunctiva of NOD/SCID-mice
(with impaired T, B, and NK cells). We noticed that primary
tumors of the xenograft showed a similarly low HLA class I
expression as the cell lines (Figs. 3, 4). In addition, a trend
toward gradually decreased HLA class I expression in the
xenografts after in vivo passaging and on a lung metastasis
was seen (Fig. 4). A lack of IFN-c production may be
responsible for this finding, as lack of lymphocytic infiltra-
tion leads to low IFN-c production. In a study on uveal
melanoma, HLA class I expression was similarly weaker in
SCID murine xenografts than in their original freshly
obtained tumors, which had shown high HLA class I
expression.35 However, another study shows an opposite
outcome: in a mouse fibrosarcoma model, a HLA class I
negative tumor clone led to HLA class I–positive spontaneous
lung metastasis in immunodeficient mice that lacked T
cells.46
TCR-based immunotherapies against cutaneous melanoma
have also been studied extensively in the last decade, using
CD8þ T cells, which recognize the tumor-associated antigens
of, among others, tyrosinase, MAGE-A1 (melanoma-associated
antigen A1), MART-1 (melanoma antigen recognized by T
cells), and glycoprotein 100 (gp100).47 In this context, a
proper HLA class I expression is needed because metastatic
cutaneous melanoma with a low HLA class I expression was
resistant to T cell–based immunotherapy and progressed.48,49
A recent study shows that mutations in B2M and IFN genes
contribute to the recurrences of four metastatic cutaneous
melanoma patients after anti–PD-1 (pembrolizumab) thera-
py.50 These findings strongly suggest that both ‘‘soft’’
(reversible) and ‘‘hard’’ (irreversible) types of absence of
HLA class I expression can influence the efficacy of T cell–
mediated immunotherapy. Our flow cytometry tests showed
that some of the HLA antigens were not expressed, even in
the presence of IFN-c, whereas other antigens showed a
higher expression following exposure to IFN-c. This indicates
that both the soft and the hard type of downregulation of HLA
expression occurs in CM. In our cohort, PD-L1/PD-1 was not
expressed on the same tumors as the HLA class I antigens.
However, it is possible that HLA class I has predictive value
concerning a tumor’s response to immune checkpoint
blockade therapy. Recent studies have shown that PD-L1
positivity is not a perfect predictor for anti–PD-L1/PD-1
treatment, because the overall response rate using PD-L1/PD-
1 inhibitors is 48% for patients with PD-L1–positive tumors,
contrary to 15% in those with PD-L1–negative tumors.51 That
HLA antigens are important was recently shown: a greater
diversity in HLA class I genotype prolongs the patients’
survival after immune blockade treatment, possibly because
the heterozygous HLA class I molecules present more tumor-
specific mutant antigens (neoantigens) to CD8þ T cells.52
Although our study contains only a small cohort from one
medical center, to the best of our knowledge, this is the first
comprehensive view of HLA class I expression of CM in vivo
and in vitro. The downregulation of HLA class I may contribute
to the mechanisms of immune escape, and limit effective T-cell
immune responses. When designing the immune-therapeutic
strategies to treat CM, one should evaluate tumor cell HLA class
TABLE 3. Results of HLA Typing in Three CM Cell Lines
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FIGURE 3. IFN-c upregulates protein and gene expression of HLA class I and increases mRNA levels of several HLA regulators in CM cell lines. Cells
were treated with or without IFN-c (100 IU/mL) exposure for 48 hours. (A) Representative histograms show the surface expression of HLA class I
(W6/32) and specific HLA allele antigens of CRMM1, CRMM2, and CM2005.1 cell lines. Histograms with red, blue and brown line represent
unstained, baseline expression, and expression after IFN-c stimulation, respectively. (B) The mRNA expression of HLA genes (HLA-A, HLA-B, B2M),
HLA transcriptional regulators (CIITA, IRF1, NLRC5), and genes encoding the peptide-loading machinery (TAP1, TAP2) were variably increased after
IFN-c stimulation. *P  0.05, using paired t-test.
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FIGURE 4. Murine xenografts maintain their HLA class I expression. Representative images present the membranous expression of HLA-A (HCA2),
HLA-B/C (HC10), and B2M in a CM2005.1 murine model. Cells from cell line CM2005.1 were first placed subconjunctivally, transferred to the
subconjunctival space of a second set of mice and spread systemically, giving rise to lung metastases. Images were taken at 3200 magnification.
TABLE 4. HLA Class I Expression in CM Murine Xenografts
Material
Staining Intensity/% Positive Tumor Cells
HLA-A (HCA2) HLA-B/C (HC10) B2M
CRMM1
Primary tumor* 2/2 (Weak) 2/2 (Weak) 3/3 (Weak)
In vivo-passaged tumor† 0/0 (Negative) 2/1 (Weak) 2/2 (Weak)
Lung metastasis‡ 0/0 (Negative) 0/0 (Negative) 0/0 (Negative)
CRMM2
Primary tumor* 2/3 (Weak) 1/2 (Weak) 3/4 (Positive)
CM2005.1
Primary tumor* 3/3 (Weak) 3/2 (Weak) 3/5 (Positive)
In vivo-passaged tumor‡ 3/1 (Weak) 3/2 (Weak) 3/4 (Positive)
Lung metastasis† 1/3 (Weak) 2/3 (Weak) 2/3 (Weak)
The staining intensity scoring system is described in the Methods.
* n ¼ 3.
† n ¼ 2.
‡ n ¼ 1.
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I expression and potentially enhance it to improve the efficacy
of T cell–based immunotherapy.
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